Industry Sponsored Program

Supported by Novo Nordisk

Alleviating burden and promoting differentiation - the lifeline for β cells: Li Guangwei, China
The effect of insulin on weight gain:  Huang Qing, China

Supported by MSD

Chairperson: Ning Guang, China
Incretin in clinical, now and future: Wang Weiqing, China
Incretin and islet function:  Peng Yongde, China

Supported by Servier

Chairpersons:  Zhu Dalong, China and Wang Weiqing, China
The Importance of Glycemic Control: Li Yan, China
The Whole Journey Management of T2DM Patients: Su Qing, China

Supported by Eli Lilly

Chairperson: Wang Weiqing, China and Shan Zhongyan, China
New GLP-RA weekly formulation, new choice to control T2DM: Li Yan, China
Open the new era of diabetes treatment:  Li Guangwei, China

Supported by Bayer

Chairperson: Ning Guang, China
Improving management of type 2 diabetes: Stimulate insulin or provide beta-cell rest?: Qu Shen, China
GUT study: the new insigth the mechanism of acarbose action and benefit: Wang Weiqing, China

12:00-12:30 | Hall B | Satellite Symposium E

Supported by Novartis

Galvus Add-on Met, best partner - Clinical significance of VERIFY study from intensive therapy: Qin Guijun, China
Galcus Add-on Insulin, perfect complement - New choice of premixed insulin combined with OAD: Peng Yongde, China

14:30-15:30 | Hall A | Satellite Symposium G

Supported by AstraZeneca

Chairperson: Wang Weiqing, China
Only one pill once a day with 3 meals PPG control: Peng Yongde, China
New choice of hypoglycemic strategy: Early use, early protection!: Zou Dajin, China

Supported by Pfizer

Chairpersons: Ning Guang, China
Statins Treatment of Type 2 Diabetes Mellitus from the Perspective of Vascular Inflammation:  Zou Dajin, China
Lipid Management of Type 2 Diabetes Mellitus from the Perspective of ASCVD Risks: Wang Weiqing

Supported by Omron

Chairperson: Ning Guang, China
Discuss the development and construction of endocrinology department from the diabetic complications screening of MMC: Wang Weiqing, China
Diabetic complications screening improve outcome of type 2 diabetes, from science to practice of MMC: Zhu Dalong, China

Supported by Hansoh Pharma

Chairperson: Ning Guang, China
Major updates on long-acting GLP-1RA for type 2 diabetes: Li Yan, China

Supported by Abbott

Chairperson: Ning Guang, China and Wang Weiqing, China
Chinese flash glucose monitoring consensus inerpretation: Li Yanbing, China
TIR: New index to evaluate short term glucose:  Wang Weiqing, China

 

Supported by Tide Pharmaceutical

Chairpersons: Liu Wei, China and Wang Weiqing, China
Interpretation of the guidelines for the prevention of type 2 diabetes: Su Qing, China

Supported by NovoNordisk

Chairpersons: Ji Linong, China
Precision medicine as general trend of the treatment - Application of GLP -1RA in new typing of diabetes: Shi Yongquan, China

Supported by CR Double-Crane

Chairpersons: Wang Weiqing, China
Combined treatment in time: Liao Lin, China

Supported by DongBao Diabetes

Chairpersons: Ning Guang, China and Wang Weiqing, China
The reasonable application of insulin in China: Guo Xiaohui, China
Discussion on Chinese Slow Disease Management Model: Xu Fengmei, China